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While the last decade has seen a growth of support for harm reduction around the world, the availability and accessibility
of quality harm reduction services in prison settings is uneven and continues to be inadequate compared to the progress
achieved in the broader community. This article provides a brief overview of harm reduction in prisons in
Catalonia (Spain), Greece, Ireland, Italy, Latvia, Poland, and Portugal. While each country provides a wide range of harm
reduction services in the broader community, the majority fail to provide these same services or the same quality of
these services, in prison settings, in clear violation of international human rights law and minimum standards on the
treatment of prisoners. Where harm reduction services have been available and easily accessible in prison settings for
some time, better health outcomes have been observed, including significantly reduced rates of HIV and HCV
incidence. While the provision of harm reduction in each of these countries’ prisons varies considerably, certain
key themes and lessons can be distilled, including around features of an enabling environment for harm reduction,
resource allocation, collection of disaggregated data, and accessibility of services.
Keywords: Prison, Prisoner, Prison health, Harm reduction, Opioid substitution therapy, Needle and syringe
programme, HIV, Hepatitis C, Human rightsBackground
The last decade has seen a growth of support for harm
reduction around the world. Harm reduction pro-
grammes are now operating at some level in more than
half of the world’s 158 countries where injecting drug
use has been documented; in other words, it is now a
majority response to drugs [1]. In Europe, the situation
appears even rosier. All 28 European Union (EU) mem-
ber states have expressed explicit support for harm re-
duction in national policies and have made needle and
syringe programmes (NSPs) and opioid substitution
therapy (OST) operational at the national level [2].
While this is a wonderful achievement, as always, there
is plenty of room for improvement. Although crucial
harm reduction services are now available in a majority
of countries, including in all EU member states, in many
countries, programmes are not operating to scale or
meeting the needs of the population they reach. Across* Correspondence: gen.sander@hri.global
1Harm Reduction International, London, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zemuch of the region, harm reduction remains unavailable
to one particularly key population: prisoners.1
Like in all other regions of the world, repressive drug
laws across Europe have resulted in people who use
drugs being overrepresented in the prison system. Cur-
rently, between 10 and 25 % of all sentenced prisoners
in Europe are incarcerated for crimes related to the use,
possession or supply of illicit drugs [3]. In 2013, an esti-
mated 230,000 supply offences and 1.1 million drug use
or possession offences were reported [3]. Prisoners re-
port higher lifetime rates of drug use than the broader
community, along with more harmful patterns of use.
Studies show that between 5 and 38 % of prisoners in
Europe admit that they have ever injected drugs [3],
while between 2 and 31 % of prisoners in the EU, de-
pending on the country, are reported to have ever
injected drugs while in prison [4]. Although they may in-
ject less frequently, prisoners are much more likely to
share injecting equipment and with a greater number of
people [4].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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poor sanitation and inadequate health care, prisons rep-
resent high-risk environments for the transmission of
human immunodeficiency virus (HIV), hepatitis C virus
(HCV) and tuberculosis (TB). This makes them import-
ant settings for the provision of evidence-based harm
reduction services, including NSPs, OST, antiretroviral
therapy (ART), opioid antagonists (e.g. naloxone),
condoms and education and information on harm
reduction.
This is also a human rights issue. Prisoners retain their
right to the highest attainable standard of health while
incarcerated, which includes a right to preventive health
services [5] and harm reduction services [6]. Denial of
these services in prison settings has also been found to
contribute to, or even constitute, conditions that meet
the threshold of ill treatment [7]. Echoing widely ac-
cepted minimum standards and guidelines on prison
health and prisoners’ rights, such as the United Nations
Basic Principles for the Treatment of Prisoners [8], many
within the UN system have now confirmed that provid-
ing harm reduction services to the general public but
not to prisoners is a flagrant violation of international
human rights law [9].
The current EU Drugs Strategy specifically identifies
scaling up the development, availability and coverage of
harm reduction measures in prison settings as a priority,
with the aim of achieving a quality of care equivalent to
that provided in the community and in accordance with
the right to health and human dignity [10]. Throughout
the EU, however, the introduction or scale up of harm
reduction measures in prisons is uneven and continues
to be inadequate compared to the progress achieved out-
side of prisons.
This article will present a brief overview of the harm
reduction situation in prisons in seven European coun-
tries: Spain (Catalonia), Greece, Ireland, Italy, Latvia,
Poland, and Portugal. A short description of the relevant
legal and policy context, available harm reduction ser-
vices in the broader community and prison health more
generally are also included to provide a better idea of
the environment in which harm reduction services
are—or are not—being provided in prison settings. This
overview is part of an EU co-funded project on HIV,
HCV, TB and harm reduction in prisons being led by
Harm Reduction International and is derived from one
of the project’s mapping components consisting a de-
tailed report on HIV, HCV, TB and harm reduction in
prisons, as well as prison monitoring practice on these
issues in each country, prepared by local researchers.2
While the provision of harm reduction in each of these
countries’ prisons varies considerably, certain key themes
and lessons can be distilled, including around features of
an enabling environment for harm reduction, resourceallocation, collection of disaggregated data and accessi-
bility of services. These will be briefly discussed in the
‘Conclusions’ section in the hopes that they can be in-
structive to countries wishing to scale up harm reduc-
tion in their prisons or to anyone advocating for harm
reduction in prisons.
Catalonia (Spain)3
Legal and policy context
Spain is made up of two autonomous cities and 17 au-
tonomous communities, one of which is Catalonia. The
country’s constitution enshrines the right to health for
all [11], and national laws and standards further protect
prisoners’ health rights [12]. Both the Spanish and Cata-
lan health systems are revered due to their extensive
coverage, but like in many other countries in the region,
the economic crisis has led to increasing privatisation
and budget cuts, all of which have impacted the entire
population’s access to health care, prisoners not
excluded.
While health care and many other issues are decentra-
lised to some degree, the central government has exclu-
sive jurisdiction over criminal law. Drug use and
possession for personal use in the country do not consti-
tute a criminal offence, although drug dealing and traf-
ficking carry heavy penalties. The Penal Code has been
amended a few times to introduce, among other things,
rehabilitative mechanisms to support people who use
drugs, such as conditional suspensions of prison penal-
ties of 5 years or less if the person is following a detoxifi-
cation programme [13].
Catalonia has certainly created an enabling environ-
ment for the implementation of harm reduction, includ-
ing in prisons. The 2009–2016 National Drug Strategy
prioritises drug-related harm reduction and harm reduc-
tion services such as NSPs, OST, drug consumption
rooms and overdose prevention programmes, including
the distribution of naloxone, have been widely available
throughout the region since the 1980s.
Prison health
In November 2014, Catalonia transferred authority for
prison health from the Department of Justice to the
Department of Health, making it the first and only au-
tonomous community in Spain to have done this. The
prison health system is now fully integrated within the
broader public health system, helping to ensure a
standard of care for prisoners that is equivalent to that
available to the broader community. The Catalan
Health Department will also soon be implementing a
new project called ‘contact nurse’, whereby some nurses
will have as their main responsibility helping to ensure
that prisoners enjoy a continuity of care following their
release [14].
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hospital in Catalonia. The prison population as of 31
December 2015 was 8810 [15],4 20.02 % of which were
incarcerated on drug trafficking charges [15]. While no
official data on drug consumption or injection within
prisons is available, official data on HIV, HCV and TB in
Catalan prisons are published online and updated every
3 months. In 2014, 92 % of the prison population under-
went voluntary screening for HIV, viral hepatitis and tu-
berculosis [16]. Voluntary tests are offered every
6 months within Catalan prisons, and treatment is initi-
ated immediately following any detection of disease. In
2014, 1427 prisoners were living with HCV and 519 with
HIV, approximately 73.4 % of which contracted the virus
through sharing injecting equipment [17]. While preva-
lence rates have been steadily declining in Catalan
prisons—for example, HCV prevalence has decreased
from 43.6 to 19.2 % since 2004 [18]—they continue to
be much higher than in the broader Catalan community.
Specifically, TB rates are 10 times higher, HCV rates 7.2
times higher, and HIV rates 20–28 times higher. Unfor-
tunately, none of the official statistics on communicable
diseases in prisons are disaggregated on any of the pro-
hibited grounds of discrimination,5 making it difficult to
identify any glaring disparities.
Harm reduction in prisons
The first harm reduction initiatives in Catalan prisons
were introduced in the 1980s and involved raising
awareness about safer injecting practices and distribut-
ing hygienic packs containing brushes, blades and
bleach. OST was first made available in some prisons in
1993, amidst much controversy and scepticism [16]. Its
uptake and success, however, led to its expansion.
Today, OST is now available across all Catalan prisons
and it is considered a low-threshold programme, mean-
ing that very few conditions must be met in order to
register. In 2014, 1300 prisoners were registered in the
OST programme, 200 of which enrolled that year [16].
This number has been decreasing over the years, how-
ever, likely due to a reduction in injecting drug use in
the community. In 2014, only 7 % of new prisoners self-
identified as injecting drug users [16].
Due to serious opposition from the prison workers’
union for many years, NSPs did not become available in
Catalan prisons until much later. Today, however, NSPs
are provided in all Catalan prisons except for the Centre
Penitenciari d’Homes de Barcelona, which holds mainly
pre-trial detainees. Most doctors and nurses, however,
believe that, in accordance with international guidance,
they should also be provided there. NSPs are situated in
prison health centres and are run by prison health care
staff members. Prisoners who are registered in the
programme are able to go to the health centre to collectsterile injecting equipment without needing to provide
an explanation to prison guards or others and are also
allowed to keep injecting equipment in their cells. For
safety reasons, bowls are not included in the injecting
equipment package that is available to prisoners, which
means that the programme is not as complete as the
one provided in the broader community. This, alongside
concerns about confidentiality, may partially explain why
only 5–6 % of people who inject drugs in prisons regis-
tered in the needle and syringe programme [16].
Condoms are generously distributed within all Catalan
prisons. They are included in hygiene packs that are
regularly supplied to prisoners and are provided for con-
jugal visits and more generally upon request.
Finally, a programme for safer tattooing targeted at
youth was piloted in 2010–2011. A professional tattoo
artist was made available within the prison, and informa-
tion on safer tattooing was provided. Tattoo restrictions,
however—and in particular those associated with gang
symbols—made the programme unappealing to pris-
oners and it was ultimately discontinued due to low
interest.
Greece6
Legal and policy context
The right to health of all citizens is protected in Greece’s
national law. As is often case, however, there is a clear
disjunction between law and practice, particularly since
the financial crisis and austerity measures triggered the
implosion of the country’s already weak social welfare
system. While this has been felt across all sectors, the
health sector has suffered the most, with serious cuts to
financial and human resources resulting in fewer and
poorer quality services across the country, including in
prisons.
Although drug use, possession and trafficking have
been criminalised and punished by imprisonment in
Greece by various laws since 1919, the most recent drug
law (4139/13) is based on the philosophy that people
who use drugs should not be treated as criminals, but
rather as ‘patients’ [19]. Despite these changes, as of 1
January 2015, 25 % of the prison population was being
held on drug charges [20].
Harm reduction service provision was scaled up in
Greece following an outbreak of HIV among people who
inject drugs in Athens in 2011. Today, low-threshold
services implement a broad range of harm reduction in-
terventions, mostly in the Greater Athens area and
Thessaloniki, including NSPs, OST, overdose prevention,
condom provision and printed health education and in-
formation materials on safer drug use and available ser-
vices [21]. Today, OST is available in most cities and
provided by OKANA, the only agent legally permitted to
do so. Waiting times are generally low, apart from in
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3.5 years to access the service. In October 2013, a drug
consumption room was opened as a pilot project but,
due to delays in establishing a valid legal basis for its op-
eration, it was suspended in July 2014 [22].
Prison health
Prison health, which is under the authority of the Ministry
of Justice, has also been affected by the financial crisis.
Not only have prisons themselves experienced serious cut-
backs, including to health care staff, but civil society orga-
nisations have also had their budgets slashed, resulting in
many having to withdraw the health services they were
providing in prison settings. Only one prison in Greece
has a hospital onsite, while all other prisons are visited by
external doctors on specific days and during specific times.
Effectively, this means that prisoners have no direct access
to health services, which is a violation of the principle of
equivalence.
As of January 2015, there were 11,798 prisoners, in-
cluding pre-trial detainees, in 35 different institutions
[23].7 Very few studies have been done on health in
prisons, and national data on health is not disaggregated
by legal status. At the prison level, there is no standar-
dised system in place to collect data on prisoner health,
although the development of an electronic database is
now under consideration. As a result, there is currently
very little or no data on prisoners who use or inject
drugs, or who are living with HIV, HCV and/or TB,
which is problematic and makes monitoring and evaluat-
ing progress very difficult. It is safe to assume, however,
that prevalence rates remain higher than those in the
community and that injecting drug use does take place
in prisons.
The European Committee for the Prevention of
Torture and Inhuman or Degrading Treatment and the
Greek Ombudsman have found on several occasions that
lack of health care services and staff, poor sanitary con-
ditions, insufficient infrastructure and overcrowding
constitute an unhealthy and dangerous environment for
prisoners, in certain cases amounting to inhuman or de-
grading treatment [24].
Harm reduction in prisons
There is still no comprehensive, nationwide approach to
harm reduction in the Greek prison system. The law
provides that any prisoner wishing to attend a rehabilita-
tion programme can apply for release and steps are
taken to facilitate their integration into this programme
[25]. For those who stay in prison, however, most op-
tions available to them are known as ‘therapeutic pro-
grammes’, i.e. those provided by 18+ and KETHEA. They
are drug-free, focused on rehabilitation, therapy and so-
cial reintegration and often restricted to those that meetquite strict criteria, including having no history of men-
tal illness and the ability to understand Greek, despite
more than half the country’s prison population consist-
ing of non-Greek nationals [26]. Civil society has re-
ported very high mortality rates—up to 95 %—in the
first 2 weeks following the release of prisoners partici-
pating in these therapeutic programmes [24].
NSPs have never been provided in Greek prisons, and
OST only became available in 2014 in St. Stephen prison
and Korydallos Judicial prison. Run by national non-
governmental organisations (NGOs), after months of op-
eration, only 80 prisoners were accessing the service and
over 400 requests were on hold. According to recent re-
ports, OST may be scaled up in Greek prisons in the fu-
ture as efforts to include this service in OKANA’s basic
budget have apparently been underway.
Ireland8
Legal and policy context
Although the right to health has not been explicitly in-
corporated into national law in Ireland, international
treaties protecting health rights have been ratified and
everyone living in the Republic, including prisoners, is
entitled to receive health care through the public health
care system, which is managed by the Health Service
Executive.
Drugs use, possession and supply are criminalised in
Ireland. In terms of use, only prepared opium is prohibited
and punished by imprisonment and/or a fine. Possession
of cannabis carries with it a fine for the first couple of of-
fences, whereas possession of other drugs and the supply
of drugs generally immediately result in imprisonment.
Following each conviction, courts have the option of refer-
ring the ‘offender’ to medical treatment or drug treatment
courts instead of imposing the penalty, although this
appears to happen infrequently [27].
There is broad support for harm reduction in Irish
health and drug-related policies and strategies, which
have led to the implementation of some important harm
reduction services in the general community. NSPs have
been operating in the country since 1989 and are cur-
rently provided via 24 static sites, 14 outreach sites and
129 community-based pharmacies [28]. OST was intro-
duced in 1992 and is now widely available throughout
the country, including to pregnant opiate users who are
entitled to immediate access, and through specific initia-
tives targeting under-18s. OST is provided by treatment
centres, specialised general practitioners and in prisons.
In 2013, in an effort to improve the quality of the ser-
vice, new guidelines for prescribing methadone during
pregnancy were issued and the first national clinical
guidelines are currently under review [29].
With one person dying from an overdose every day,
there have been some developments in the last year to
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lising possession of small amounts of drugs and making
more harm reduction services available. In 2015, the
Health Service Executive rolled out a ‘demonstration
project’ that involved training non-medical staff, such as
care workers, family and peers, in the administration of
naloxone, which has been hailed as an important step
towards making naloxone more widely available to
people who use drugs [30]. The current Minister of State
responsible for Ireland’s Drug Strategy, Aodhán Ó Ríor-
dáin, also recently announced that the country will be
opening drug consumption rooms in four Irish cities in
2016 [31].
Prison health
As a result of the structural reforms imposed by the EU/
International Monetary Fund financial assistance pack-
age, the Irish Prison Service experienced budget cuts of
over €72 million between 2008 and 2014, despite an in-
crease in the number of prisoners [32, 33].
Prisoner health in Ireland is under the authority of the
Irish Prison Service, as opposed to the Ministry of
Health. Finalised in 2011, the health care standards for
the Irish Prison Service, which include standards on
drug treatment and communicable diseases, aim to pro-
vide prisoners with access to the same quality and range
of health services as those available to the broader com-
munity [34]. This, however, has not been the case in
practice. Health care in Irish prisons has been described
as disconnected from the national health care service
and in a state of crisis [35].
As of July 2015, there were 3771 individuals impri-
soned in 14 institutions operated by the Irish Prison
Service.9 In 2013, nearly 16 % of the prison population
were serving sentences for drug crimes [33]. The preva-
lence of drug use within Irish prisons is reported to be
much higher than in the general community, with life-
time prevalence of injecting drug use among prisoners
recorded at 25 % [36]. Data on the incidence of HIV,
HCV and TB in Ireland is not disaggregated by legal sta-
tus, so there is a serious shortage of information on these
diseases in Irish prisons. Some independent research has
been done, however, identifying HIV and HCV prevalence
at 2 and 13 %, respectively, in Irish prisons [36]. In recent
years, high incidences of TB outbreaks associated with
multi-drug resistance and HIV co-infection have been
observed in prison populations [37].
Harm reduction in prisons
Ireland’s National Drugs Strategy 2009–2016 includes a
specific focus on prisons, and action 43 refers to the
need for ‘seamless provision of [drug] treatment services’
between the prison and the broader community. As of
2014, OST was available in all 14 prisons and access tothis service was considered high [2]. Quality, however,
varies by institution. According to the Irish Prison
Service, OST provision at Mountjoy prison is currently
equivalent to OST provision in the broader community.
It includes six specialist nurses who have a distinct role
with regard to drug dependence assessment, treatment
planning, as well as delivery and evaluation of care. It
also consists of a clinical drug dependence team that is
made up of all disciplines engaged in drug treatment ser-
vices. While there are plans to make this standard of
OST available in all other prisons, particularly those
where demand for OST in high [38], the standard of
OST available in other prisons confirms there is a long
way to go. During its visit to Ireland 2014, the European
Committee for the Prevention of Torture learned that
the Limerick Prison doctor refused to prescribe metha-
done and that the ‘methadone doctor’ only visited twice
a week, resulting in a haphazard and incomplete treat-
ment programme [35]. Other known harm reduction
services available in Irish prisons include specialised
counselling or psychiatry for drug dependence, as well
as community-run counselling. NSPs and naloxone are
not currently provided.
Italy10
Legal and policy context
Italy’s 1948 constitution explicitly recognises health as a
fundamental human right, and the Italian National
Health Service was established in 1978 to facilitate uni-
versal access to a uniform level of health care that is free
at the point of use. Planning and delivery of health ser-
vices, however, has been the responsibility of autono-
mous regional governments since 2011, which has led to
the creation of 21 distinct health care systems with wide
variations in coverage of services, quality of care and, ul-
timately, health outcomes.
Drug laws in the country in the past 40 years have
fluctuated between hard line blanket prohibition ap-
proaches and more reasonable regulatory approaches,
depending on the political climate. Today, possession,
acquisition and import for personal consumption remain
prohibited but only attract administrative sanctions, and
fixed quantities are no longer applied to determine the
difference between use and traffic. Production and traf-
ficking carry with them a penalty of imprisonment and a
fine according to quantity and drug type. Offenders who
use drugs have the option of applying to join a drug
treatment programme as an alternative to incarceration,
although a judge makes the final decision on this [39].
Although Italy’s drug policy focuses more on preven-
tion and reduction of drug use than on harm reduction,
some harm reduction services are available in the coun-
try. OST (methadone and buprenorphine) and NSPs are
both available in the broader community. These are
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gions, however, which have the greatest urban densities
and where the highest numbers of people who use drugs
are reported to reside. These services are delivered
through fixed sites, mobile units, outreach programmes
and needle and syringe dispensing machines [40].
Prison health
In 2008, prison health became the responsibility of the
Ministry of Health. While this was a milestone for the
protection of prisoners’ health, the regionalisation of the
health service has led to discrepancies in service
provision and quality, as well as prisoner health out-
comes, depending on the location of the prison.
Prisoners have raised complaints about the lack of
preventive health care and delays in diagnoses.
As of 31 January 2015, there were 206 prisons in Italy
holding 53,889 prisoners.11 Although there have been
improvements regarding overcrowding in the last few
years, with the official capacity at 49,943, there are still
108 prisoners for every 100 available spaces. As of 31
December 2014, there were 18,946 prisoners incarcer-
ated for drug offences.
Data on HIV, HCV and TB in prisons is scarce. Each
region is responsible for data collection; some regions,
however, do not gather data systematically, and if it is
gathered, it is not shared with the Ministry of Health or
Justice. The Ministry of Health and the Regional Health
Agency of Tuscany collected the most recent data from
58 prisons spread over six regions. Of 15,751 prisoners
tested, 7.4 % were found to be living with HCV, 2 % with
HIV and 0.6 % with TB [41]. These figures are much
higher than those in the broader community, particularly
with regard to HCV, which is three times higher among
prisoners [41]. This data was also disaggregated by sex-
ual identity, age and ethnic group, which revealed sig-
nificant discrepancies. Transgendered prisoners, for
example, were found to be considerably more likely to
be living with HIV and/or HCV, indicating that special
measures should be taken target this group with volun-
tary and confidential prevention, harm reduction and
treatment services.
Harm reduction in prisons
NSPs, overdose prevention programmes and condoms
are not currently available in Italian prisons. OST is pro-
vided through public drug dependence service units
(SerTs), which receive legislated public funding. SerTs
have contracts with 80 % of prison facilities, while the
remaining 20 % work on a demand or request basis. Un-
fortunately, no data is currently being collected on the
effectiveness of the service, which is not as widespread
as it could be due to a lack of support among politicians
and prison authorities. Generally speaking, admitting tothe need for harm reduction services in prisons is con-
sidered an acknowledgement that existing programmes
in the broader community have failed.Latvia12
Legal/policy context
The right to health is enshrined in article 111 of the
Latvian Constitution, which provides that the State must
protect health and guarantee a basic level of medical as-
sistance for everyone [42]. Unfortunately, this remains dif-
ficult to uphold in practice because Latvia’s health system
has one of the lowest levels of funding in the EU [43].
Drug use in Latvia is charged as an administrative
offence, punished by a warning or a fine of up to 280
euros, though repeat use within 1 year is a criminal
offence. Similarly, drug possession for personal use may
be charged as a criminal or administrative offence de-
pending on the quantity. People with a drug dependency
may be exempted from punishment if they voluntarily
agree to undergo treatment.
Harm reduction is supported in Latvia. The first NSP
began operating in 1997, and today, a network of low-
threshold centres for people who use drugs operate
throughout the country, providing NSPs, outreach, vol-
untary HIV testing and counselling, HCV testing, disin-
fectants, condoms and harm reduction information and
education [44]. OST has been available since 1996, and
the service is now fairly widely available thanks to a
change to the legal framework in 2012 requiring broader
provision through general physicians who have com-
pleted special training. The regulation also provided for
continuity of OST provision in prison. Methadone is
provided free of charge, while buprenorphine is available
at the patient’s expense. While these changes contrib-
uted to a threefold increase in the number of people re-
ceiving OST between 2006 and 2012, Latvian coverage
rates are still the lowest in the EU [45]. Following the fi-
nancial crisis in 2009, national structural reforms further
impacted the availability and quality of existing harm re-
duction services. Several agencies working on harm re-
duction were closed and funding for NGO-run
programmes became even more limited [46].Prison health
Prison health care is separated from the general health
care system in Latvia. Although HIV and TB prevention
and treatment in prisons are funded under the health
budget as part of a national programme run by the
Ministry of Health, prison health care is organised and
funded by the Ministry of Justice and all prison health
care services are provided by the Latvian Prison Admin-
istration [47]. As a result of the economic crisis and cuts
to public spending, Latvia’s prison budget shrank by
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on the prison health service.
Latvia has 11 prisons and 4745 prisoners, including
pre-trial detainees. The prison population rate, a stagger-
ing 239 per 100,000 inhabitants, remains one of the
highest in the EU. In 2014, according to the Latvian
Prison Administration, 618 prisoners self-identified as
drug users, while 1059 cases of drug use within prisons
were recorded, 763 (72 %) of which were through
injection [49].
There is no uniform procedure for health care report-
ing and data collection in Latvian prisons [50], which
means that existing data on HIV, HCV and TB preva-
lence vary quite significantly and are not very reliable.
Data provided by the prison administration, however,
suggests that in 2013, 13 % of prisoners were living with
HIV, while 34 % were living with HCV [51]. Despite the
discrepancies in data and a lack of disaggregation, preva-
lence rates, as well as the risk of infection, remain much
higher in prisons than in the broader community [52].
In 2011, the European Committee on the Prevention of
Torture noted that, despite the large proportion of pris-
oners living with HIV, extremely limited arrangements
had been made to provide for their appropriate care. In
particular, a very small number of these prisoners were
receiving antiretroviral therapy (e.g. three out of 47 in-
mates at Jelgava Prison; four out of 68 at Valmiera
Prison). Furthermore, it appeared that no information
on HIV, HCV and prevention methods was made avail-
able to staff and prisoners [53]. In addition, general
screening for HCV is not provided in prisons; only when
prisoners show symptoms can they be tested.
Harm reduction in prisons
Although harm reduction implementation appears in
many prison policies and strategies in relation to health
and drugs, harm reduction in Latvian prisons primarily
takes the form of information and education campaigns,
which are largely provided by the Centre for Disease
Prevention and Control and various national NGOs. The
provision of free condoms is considered insufficient,
there is no NSP provision, and OST (methadone) is only
available to prisoners who were receiving it prior to in-
carceration because there are no medical professionals
qualified to provide the service within prisons. In 2014,
28 prisoners were able to continue OST upon incarcer-
ation, up from 11 the previous year.13
According to civil society, harm reduction services are
very difficult to implement in Latvian prisons at the mo-
ment due to a shortage of financial and human resources
for health, inadequate prison infrastructure, and a lack
of education on drugs and health among prison em-
ployees. There are also serious reservations regarding
the provision of NSPs. Essentially, experts in the countrybelieve that making NSPs available in prisons would im-
plicitly acknowledge the availability, and condone the
use, of drugs in prison settings, thereby undercutting the
objectives of drug prohibition [54].
Poland14
Legal/policy context
Poland’s 1997 Constitution protects the right to health,
including access to health services, and imposes positive
obligations on state authorities to combat the spread of
epidemics [55]. The country’s drug laws and policies,
however, are some of the most restrictive in the EU. The
use, possession, production and trafficking of drugs are
all prohibited. The possession of even a small amount of
drugs carries a 3-year prison sentence [56]. In 2011, the
law was amended (clause 62a) to allow for the suspen-
sion of criminal proceedings for possession of drugs
intended only for personal use. This flexibility clause,
however, has not been applied evenly across the country
due to a lack of training on it. In 2013, only around
25 % of all drug possession cases were suspended [57].
Harm reduction enjoys some support in Poland. Harm
reduction services have been available to some extent
since 1989, and consist of NSPs, OST, and the provision
of prevention-related information [58]. In 2013, 13 NSPs
were operating in 10 cities, generally run by NGOs, but
coverage has actually been declining since 2002 due to a
variety of factors, including a lack of funding [58]. OST
is currently available at 31 different public and private
health care facilities throughout the country and, accord-
ing to national data, between 13 and 26 % of people who
use opioids (2061 people) are accessing this service. This
percentage, however, does not include prisoners.
Prison health
The economic crisis led to a 175 million Euro decrease
in prison expenditures between 2008 and 2012. This has
inevitably had a negative impact on prison health, which
is under the authority of the Ministry of Justice. No
plans are currently in place to transfer this responsibility
over to the Ministry of Health.
There are 150 penitentiary units in Poland, 60 % of
which are prisons. As of 24 July 2015, there were 74,234
inmates, 68,000 of which had been convicted.15 While
there is no data on the number of people incarcerated
for drug offences at any given time, according to the
Ministry of Justice, over 10,000 people were convicted
for drug possession in 2014 [59].
According to the Polish Prison Service, approximately
4000 prisoners are voluntarily tested for HIV and 9000
for HCV every year. Of these, between 30 and 50 new
HIV infections and nearly 400 new HCV infections are
detected every year [60]. Access to ART in prisons has
increased in the last 5 years [60], and currently, every
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Data relating to HIV in Polish prisons, however, is not
considered to be very reliable. Prisoners’ have com-
plained about their HIV status being disclosed to prison
officers, leading many to hide their status. There have
also been reports of a lack of skilled physicians resulting
in long waiting times for specialist medical consulta-
tions, as well as the fact that some physicians are also
part of the prison service [62].
Harm reduction in prisons
NSPs and information on safer injecting are not cur-
rently available in Polish prisons because authorities be-
lieve this would imply support for drug use during
incarceration. Of the 31 OST programmes available
throughout Poland, seven are operating across 27
prisons. Although methadone is the most common agent
prescribed, buprenorphine, suboxone and other substi-
tutes are also available. Since OST became available in
2003, only 468 prisoners have accessed the service, and
according to data obtained from the Polish Prison
Service, the number of prisoners accessing the service is
decreasing every year [63].
According to the Director of Poland’s Harm Reduction
Foundation, Magdalena Bartnik, the provision of OST in
the country, including in prisons, is problematic. The
service pursues the ultimate goal of abstinence and con-
ditions often apply to the actual provision of OST.
Those enrolled in the programme are tested for the
presence of drugs other than the substitute, and for
those not incarcerated, if a test comes back positive, they
are unable to take the substitute home. For prisoners,
the treatment is not holistic. There is an apparent lack
of HIV and HCV prevention, treatment and care and no
real provision of social support, including in the process
of re-integrating into the broader community. Further-
more, there is no evaluation on the effectiveness of OST
in prisons [64]. The European Committee on the Pre-
vention of Torture has said that interviews with prison
doctors revealed a high amount of scepticism around
the implementation of OST in Polish prisons [65]. The
monitoring mechanism has recommended that the
Polish government develop and implement a compre-
hensive policy for the provision of care to prisoners with
a drug dependence, though there are still no signs that
steps are being taken to this effect.
Portugal16
Legal and policy context
Portugal’s constitution enshrines the right to health and
establishes the country’s National Healthcare Service
[66], which is charged with ensuring every citizen’s pre-
ventive, curative and rehabilitative medical needs. As is
the case in many countries, however, there is significantgap between law and practice, especially in prison con-
texts. The on-going economic crisis has resulted in ser-
ious cutbacks, especially to the public health and prison
sectors.
Portugal has supported harm reduction since the
1970s. The first OST programme was initiated in
Boavista in 1977, and shortly thereafter the first Centre
of Integrated Responses opened, providing treatment,
prevention, harm reduction and reintegration services to
people who used drugs through multi-disciplinary teams
of doctors, nurses, psychologists and social workers [67].
In 1993, a national NSP was implemented in pharmacies
across the country. By 1997, a national network of sup-
port had been developed for people who use drugs, cov-
ering every district and providing a wide range of
services, including harm reduction [68]. Despite these
efforts, in 1999, Portugal had the highest HIV prevalence
rate among people who inject drugs in the EU [69]. The
National Strategy to Fight Drugs adopted that same year
and overseen by the Ministry of Health, embraced harm
reduction as part of an integrated national strategy. A
radical policy shift followed in 2001, in which Portugal
decriminalised all drug use, as well as purchase and pos-
session of drugs deemed reasonable for personal use.
Today, harm reduction in Portugal is coordinated by the
government-run General Directorate for Interventions
on Addictive Behaviours and Dependencies (Serviço de
Prevenção e Tratamento da Toxicodependência, SICAD)
and consists of free or very inexpensive medical checks;
free psychosocial assessments; free, voluntary and confi-
dential blood sample collections; free OST and NSPs;
and social support services.
Prison health
Despite the integration of prison healthcare into the
National Healthcare Service in 2007, many health ser-
vices are still being provided by the prison system and
there appears to be a growing trend towards outsourcing
prison healthcare to private contractors. Prisoner com-
plaints collected by civil society expose prison health
care as being highly ineffective due to a lack of medicine,
medical staff, treatment, access to basic diagnostic care
and transportation.
There are currently 49 prisons in the country, includ-
ing one prison hospital. As of 31 December 2014 there
were 14,003 prisoners, about 16 % (2217) of which were
incarcerated for drug-related offences [70].17 Official
data on drug use and prevalence rates of HIV and HCV
within prisons is scarce due to the absence of an infor-
mation system on prison health, as well as difficulty in
getting prison authorities to collaborate with informa-
tion requests. A National Inquiry into Addictive Behav-
iours within Prison recently undertaken revealed that of
a 20 % sample of all prisoners from 47 of the 49 prisons,
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tive, compared to 10 % in 2007 and 16.3 % in 2001
[71]. Of that same sample, 69.1 % reported using drugs
at any point during their lives, 47.9 % of which had
used drugs in prison. SICAD’s 2014 annual report re-
veals that of the 1524 prisoners participating in its drug
treatment programmes, 15 % were living with HIV and
42 % with HCV. Of the 15 % living with HIV, 76 %
were receiving antiretroviral treatment, and 59 % were
HCV co-infected [72].
Harm reduction in prisons
The various National Strategies to Fight Drugs have out-
lined a series of harm reduction services to be imple-
mented in prisons, which have focused on facilitating
access to condoms and bleach, staff training and preven-
tion programmes [67].
Following ten years of fervent opposition from prison
security staff unions, in December 2007 a pilot NSP
mandated by Parliament ran for six months in two
prisons. Unfortunately, despite guarantees of confi-
dentiality, not a single prisoner participated in the
programme during that time, leading to the pilot’s ter-
mination. A subsequent study revealed that prisoners’
had in fact feared being discriminated against by, and
suffering reprisals at the hands of, prison authorities for
their participation in the NSP. The same study revealed
that 60 % of the staff at the two participating prisons
thought this fear was well founded [73]. At present there
are no NSPs available in Portuguese prisons, despite
continued reports of prisoners sharing injecting equip-
ment during incarceration [71].
Pilot OST programmes, using methadone and funded
by the Directorate-General of Prisons services, were ini-
tiated in prisons in Lisbon and Porto in the 1990s. Fol-
lowing evaluations that yielded positive results in 1999,
two more programmes were launched. OST has since
become the most widespread harm reduction service
available in the country, and is currently available, at
least in principle, in all 49 prisons in the country. A
study of a 20 % sample of the prison population revealed
that of the 69.1 % who acknowledged having consumed
drugs at any point during their lives, 45.6 % have been
in a treatment programme18 at some point outside of
prison; 18.6 % are currently in a treatment programme
in prison, and 27.4 % has already been in a treatment
programme in prison. Of that same sample, 13.8 % ac-
knowledged having injected drugs outside of prisons,
while 1.1 % acknowledged injecting during their incar-
ceration, compared to 20.6 % and 3.1 % respectively in
2007 and 32.3 % and 11.3 % in 2001 [71]. While this cer-
tainly demonstrates progress, some problems remain.
According to civil society organisation Groupo de Ativis-
tas em Tratamento (GAT), OST is occasionally offeredaccording to institution-specific policies, which may not
follow national guidelines. Prisoners have also com-
plained of long waiting times and other difficulties in
accessing OST while in prisons [74]. Members of
SICAD, the only authorised methadone distributer in
the country and the body currently funding and provid-
ing OST in prisons nationwide, have also privately
expressed frustration with barriers to accessing OST in
prisons [75].
The same national study on a 20 % sample of the
prison population revealed that 79 % of the sample had
never used condoms during conjugal visits, while 72.1 %
acknowledged having never used condoms in other con-
texts, suggesting that condoms are either not available
or not easily accessible in Portuguese prisons [71].
Conclusions
As this overview illustrates, the provision of harm reduc-
tion in prisons continues to be largely inadequate com-
pared to the progress achieved outside of prisons. All of
the countries reviewed provide a wide range of harm re-
duction services in the broader community, but the ma-
jority fail to provide these same services, or the same
quality of these services, in prison settings, in clear vio-
lation of international human rights law and minimum
standards on the treatment of prisoners. Where harm
reduction services have been available and easily access-
ible in prison settings for some time, better health
outcomes have been observed, including significantly
reduced prevalence and incidence of HIV and HCV.
While there is no blueprint or ‘one size fits all’ ap-
proach to implementing harm reduction in prison set-
tings, certain themes and lessons can be drawn from
these countries’ experiences that may be instructive for
other countries committed to introducing or scaling up
harm reduction in prison settings, or useful for anyone
advocating for harm reduction scale up in prisons.
First, the implementation and success of harm reduc-
tion approaches and services in prisons, as demonstrated
by the Catalan experience, appear to be facilitated by an
enabling environment with a range of features. To begin
with, a supportive legal and policy context is indispens-
able. This should include, at the very least, the legal rec-
ognition and protection of human rights, including the
right to health for everyone, the decriminalisation or le-
galisation of drug possession for personal use and expli-
cit support for harm reduction, including in prisons, in
national policies. A strong and well-funded public health
system with extensive coverage and within which prison
health is truly integrated is also very important. In this
regard, prison health should fall under the responsibility
of health ministries, as opposed to ministries of justice
or interior, to help ensure that prison health policies and
services are integrated into, and compatible with,
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equate continuity of care upon prison entry and release.
While decentralisation of power, including of health ser-
vices, is great step in protecting the rights and interests
of local populations, steps must be taken to ensure the
same, high-quality standard of care for everyone, includ-
ing prisoners. Finally, it appears that prison authorities
can have a significant amount of influence over whether
or not harm reduction services are provided in prison
settings. Increasing efforts at the national level to engage
these key actors, including providing quality training on
human rights and harm reduction, would likely go a
long way in gaining their support.
Another major theme emerging from this overview is
the incredible shortage of resources for harm reduction,
as well as the vulnerability of harm reduction pro-
grammes to funding cuts. Every country in this overview
has been heavily impacted by the financial crisis, with
national health and prison budgets suffering extensive
cuts, and harm reduction programmes—inside and out-
side of prisons—being discontinued. At the same time,
international donors are shifting their funding for harm
reduction from middle-income countries to low-income
countries, maintaining that these countries can now af-
ford to provide health services without international as-
sistance [1]. This funding crisis for harm reduction,
however, is not always a question of a deficiency of re-
sources but often of a misallocation of resources. In
those countries with punitive drug laws, a lot of re-
sources end up being spent on ineffective and often
damaging drug law enforcement approaches instead of
on interventions that could promote the rights, health
and dignity of people who use drugs. Financial and hu-
man resources for the provision of quality harm reduc-
tion services within prison settings must urgently be
scaled up to correspond with need, which, as this study
confirms, continues to be very high.
This overview also reveals a striking scarcity of data
available on health, drug use and harm reduction in
prisons. Where data are available, they are often either
very difficult to access or conflict with other available
data, and are rarely, if ever, disaggregated on any of the
prohibited grounds of discrimination, making it difficult
to identify gaps and disparities. There is an urgent need
for national collection of reliable data in relation to
harm reduction, drugs and HIV, HCV and TB in prisons
settings to enable quality monitoring and evaluation of
the effectiveness of policies and services. This should be
undertaken in a transparent, systematic and comprehen-
sive manner and should be made widely available to the
public.
Finally, at the service provision level, an important
lesson on accessibility and coverage can be distilled from
the overview. Above all, just because a service isavailable does not mean it is accessible. Concrete steps
must be taken to ensure greater accessibility. While all
countries reviewed provide OST in prisons, accessibility
to this service varies considerably and would be en-
hanced if, as a first step, all conditions and restrictions
on eligibility were lifted. For example, OST provision
should not be limited to those who were already receiv-
ing it prior to incarceration. Nor should it be dependent
on passing mandatory drug tests or enjoying good men-
tal health. Nor should it be conditional on one’s ability
to understand a certain language or provided as part of
an abstinence-based approach for detoxification. These
all act as obstacles to access. The less restrictions and
conditions there are, and the more harm reduction ser-
vices are tailored to the specific needs of prisoners, the
more accessible they become. In this regard, prisoners
should to meaningfully participate in the development,
implementation and monitoring and evaluation of
prison-based harm reduction policies and programmes.
Furthermore, policy makers and prison authorities
should consult important guidance on prison-based
harm reduction services developed by the World Health
Organization, United Nations Office on Drugs and
Crime and UNAIDS when developing and implementing
harm reduction services in prison settings.19
Throughout the EU, the availability and accessibility of
quality harm reduction services in prisons is uneven and
continues to be inadequate compared to the progress
achieved in the broader community. It is imperative this
gap be closed by immediately scaling up, and ensuring
access to, a wide variety of harm reduction services in
prisons. It is imperative to achieving important global
targets on HIV, HCV and TB, to fulfilling prisoners’ in-
alienable human rights and to treating prisoners with re-
spect for their inherent dignity and value as human
beings.Endnotes
1The term ‘prisoner’ throughout this article refers to
all people deprived of their liberty, including pre-trial
detainees, while the term ‘prison’ refers to all detention
facilities.
2For more information, please visit Harm Reduction
International’s webpage on the project at: http://www.ih
ra.net/prison-project
3The original report, co-authored by Cristina Fernández
Bessa, Gemma Nicolás Lazo and Gerard Viader Sauret,
Improving Prison Conditions by Strengthening the Moni-
toring of HIV, HCV, TB and Harm Reduction: Mapping
Report Catalonia (Spain), (2016), is available at: http://
www.ub.edu/ospdh/sites/default/files/documents/public
acions/improving_prison_conditions_ospdh_2016_repo
rt.pdf. Most, if not all, of the research in this subsection is
Sander et al. Harm Reduction Journal  (2016) 13:28 Page 11 of 13derived from the original report, and all references have
been reproduced.
4In 2014, Catalonia’s incarceration rate was 123 pris-
oners per 100,000 inhabitants.
5International human rights law prohibits discrimin-
ation on the grounds of race, colour, sex, gender, lan-
guage, religion, political and other opinion, health status,
legal status, national or social origin or any other status,
such as age and sexual orientation.
6The original report by PRAKSIS—Programme of
Development, Social Support and Medical Cooperation,
Improving Prison Conditions by Strengthening the Moni-
toring of HIV, HCV, TB and Harm Reduction: Mapping
Report Greece, (2015) is available at http://www.prak-
sis.gr/assets/PrisonProjectReport_Greece.pdf. Most, if not
all, of the research in this subsection is derived from the
original report and all references have been reproduced.
7In 2015, Greece’s prison population rate was 109 per
100,000 inhabitants.
8The original report, co-authored by Catherine MacNa-
mara, Lorraine Varley and Patricia Mannix McNamara,
Improving Prison Conditions by Strengthening the Moni-
toring of HIV, HCV, TB and Harm Reduction: Mapping Re-
port Ireland, (2015), is available at http://www.iprt.ie/files/
PrisonProjectReport_Ireland_print_A5.pdf. Most, if not
all, of the research in this subsection is derived from the
original report, and all references have been reproduced.
9In 2015, Ireland’s prison population rate was 80 per
100,000 inhabitants.
10The original report, co-authored by Alessio Scandurra,
Sandro Libianci and Grazia Parisi, Improving Prison Condi-
tions by Strengthening the Monitoring of HIV, HCV, TB and
Harm Reduction: Mapping Report Italy, (December 2015),
is available at http://www.associazioneantigone.it/upload2/
uploads/docs/Report_Italy_ENG.pdf. Most, if not all, of the
research in this subsection is derived from the original re-
port and all references have been reproduced.
11In 2015, Italy’s prison population rate was 86 per
100,000 inhabitants.
12The original report, co-authored by Anhelita
Kamenska (Latvian Centre for Human Rights) and Solvita
Olsena (University of Latvia, Faculty of Medicine), Improv-
ing Prison Conditions by Strengthening the Monitoring of
HIV, HCV, TB and Harm Reduction: Mapping Report
Latvia, (2015), is available at http://cilvektiesibas.org.lv/
en/publications/improving-prison-conditions-by-strength-
ening-the-m-398/. Most if not all, of the research in this
subsection is derived from the original report and all refer-
ences have been reproduced.
13Data included in the report of Latvian Prison
Administration states that 11 prisoners were provided
substitution therapy in 2013; however, in the Final
Report regarding implementation of the Programme
for the Limitation of Spreading of the HumanImmunodeficiency Virus (HIV) Infection for 2009–2013
other numbers are reported.
14The original report, co-authored by Marcin Wolny
and Piotr Kubaszewski, Improving Prison Conditions by
Strengthening the Monitoring of HIV, HCV, TB and Harm
Reduction: Mapping Report Poland, (2015), is available at
http://www.hfhr.pl/wp-content/uploads/2016/06/Prison
ProjectReport_Poland-1.pdf. Most, if not all, of the re-
search in this subsection is derived from the original re-
port and all references have been reproduced.
15In 2015, Poland’s incarceration rate was 191 per
100,000 inhabitants.
16The original report, co-authored by Nuno Henrique
Pontes and António Pedro Dores, Improving Prison Con-
ditions by Strengthening the Monitoring of HIV, HCV, TB
and Harm Reduction: Mapping Report Portugal, (2015),
is available at http://home.iscte-iul.pt/~apad/PrisoesEur
opa/observatorio/PROJ%20INFECTIOUS%20DISEASE/
PrisonProjectReport_Portugal.pdf. Most, if not all, of
the research in this subsection is derived from the ori-
ginal report and all references have been reproduced.
17In 2015, Portugal’s incarceration rate was 138 per
100,000 inhabitants.
18‘Treatment programmes’ here refer mainly to OST
programmes, but also likely include abstinence pro-
grammes and rehabilitation.
19See, for example, WHO, UNODC, UNAIDS. Evidence
for Action Technical Papers: Interventions to ddress HIV in
Prisons - Drug Dependence Treatments. Geneva: 2007.
Available at: https://www.unodc.org/documents/hiv-aids/
EVIDENCE%20FOR%20ACTION%202007%20drug_treat-
ment.pdf; UNODC. A Handbook for starting and man-
aging needle and syringe programmes in prisons and other
closed settings. No date provided. Available at: https://
www.unodc.org/documents/hiv-aids/publications/Pris-
ons_and_other_closed_settings/ADV_COPY_NSP_PRI-
SON_AUG_2014.pdf; and WHO, UNODC. Opioid
Substitution Treatment in Custodial Settings: A Practical
Guide. Germany: 2008. Available at: http://www.unod-
c.org/documents/hiv-aids/OST_in_Custodial_Settings.pdf
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